Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial

K Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, Ola Weiland, Andrzej Horban, Carol Stanciu, Federico Guillermo Villamil, Pietro Andreone, Jacob George, Elisabeth Dammers, Min Fu, Darryl Kurland, Oliver Lenz, Sivi Ouwerkerk-Mahadevan, Thierry Verbinnen, Jane Scott, Wolfgang Jessner
  • The Lancet Infectious Diseases, January 2015, Elsevier
  • DOI: 10.1016/s1473-3099(14)71002-3
The author haven't finished explaining this publicationThe author haven't finished explaining this publication
Read Publication

The following have contributed to this page: Dr Thierry Verbinnen